Background: Colistin is commonly needed for the treatment of infections due to carbapenem-resistant Acinetobacter baumannii (CRAB) and the determination of its in vitro activity is obviously important. However, the accurate routine antimicrobial susceptibility testing (AST) of colistin is still challenging. The only acceptable method for colistin AST is broth microdilution (BMD); disc and gradient diffusion assays are inappropriate and the performance of semi-automated systems has not been validated.
Introduction
Colistin is increasingly needed for the treatment of infections caused by carbapenem-resistant Acinetobacter baumannii (CRAB) isolates. 1 The accurate antimicrobial susceptibility testing (AST) of colistin is of obvious importance; however, considerable discrepancies have been reported between the available assays. To address this issue, EUCAST and CLSI recently formed a Polymyxin Breakpoints Working Group for colistin susceptibility testing, 2 which recommended that broth microdilution (BMD) is the most valid method for colistin AST. Among the diffusion methods, disc diffusion is unacceptable due to the large colistin molecule, while several studies in the literature have reported considerable discrepancies of the MICs produced by gradient tests. 3 The joint EUCAST/CLSI working group recently confirmed the problems that both of the available colistin gradient tests (manufactured by bioMérieux and Liofilchem) exhibit. 4 As far as the widely available commercial automated systems that include colistin AST are concerned, few reports have tested Vitek2, while, to the best of our knowledge, Phoenix100 has not been evaluated. The above EUCAST/CLSI working group recently evaluated agar diffusion methods on 75 Enterobacteriaceae, Pseudomonas aeruginosa and Acinetobacter spp. isolates with varying colistin susceptibility, but has not yet tested systematically Vitek2 and Phoenix. 4 In this respect, the routine clinical laboratories have particular challenges in identifying the in vitro activity of colistin. To address this issue, we present here the results of colistin AST performed by Phoenix100 and Vitek2, compared with two standard dilution methods, on a collection of 117 CRAB isolates. throughout Greece were tested. The isolates were identified as A. baumannii by PCR for the intrinsic bla OXA-51-like gene and the identification was validated by sequencing of the amplicon, by which all isolates were effectively assigned to known international clones (ICs) that are specific for A. baumannii. 5 In particular, by this typing approach [single-locus bla OXA-51-like sequence-based typing (SBT)], 6 25 isolates belonged to IC1 and 92 to IC2. The clonality of the isolates was further tested by PFGE, performed on selected IC1 and IC2 isolates, by which several different PFGE types and subtypes were identified within each lineage. 5 All isolates were carbapenem resistant, which is currently the case for .93% of clinically important A. baumannii in Greece. 7 Colistin susceptibility levels were determined by Vitek2 Compact (bioMérieux, Marcy-l' Etoile, France), using the Vitek2 AST XN05 Card, and by Phoenix100 (Becton Dickinson, Sparks, MD, USA), using the Phoenix NMIC/ID-96 Panel, according to the manufacturers' recommendations. For the agar dilution (AD) method, colistin sulphate powder (batch number SLBK0713V; Sigma-Aldrich, St Louis, MO, USA) was incorporated into Mueller-Hinton II agar (SigmaAldrich, Taufkirchen, Germany) plates at concentrations of 0.5-8 mg/L and with a final inoculum of 10 4 cfu/spot. BMD was applied using the CLSI-recommended guidelines. 8 Briefly, 2-fold dilutions with a range of 0.5-8 mg/L colistin sulphate salt (Sigma-Aldrich) were prepared in 96-well untreated polystyrene trays, using a final inoculum of 5%10 5 cfu/mL of each isolate in CAMHB BBL (Becton Dickinson). All methods were performed in triplicate using a single inoculum for each strain and the assay results were recorded by two blinded observers. Escherichia coli ATCC 25922 and P. aeruginosa ATCC 27853 were used as susceptible controls, 9 while resistant controls were the well characterized colistin-resistant A. baumannii strains Ab299 and Ab347. 10 The susceptibility/resistance breakpoints recommended by CLSI and EUCAST for A. baumannii (S2/R4 mg/L and S2/R.2 mg/L, respectively) 9 ,11 were applied. As recently recommended by the joint EUCAST/ CLSI working group, the BMD method was used as the reference method 2 against which the MICs produced by Phoenix100/Vitek2/AD were compared. Categorical agreement (CA) represented the rate of isolates grouped in the same susceptibility category by Phoenix100, Vitek2 or AD compared with BMD, and essential agreement (EA) was the rate of isolates that differed by one doubling dilution by Phoenix100, Vitek2 or AD compared with BMD, as recommended by the International Organization for Standardization (ISO) standard 20776-2.
12 Very major errors (VMEs) were isolates that were susceptible to colistin by Phoenix100, Vitek2 or AD and resistant by BMD; major errors (MEs) were isolates categorized as resistant by Phoenix100, Vitek2 or AD but susceptible by BMD. 12 To allow comparison of CA, Phoenix100 MICs of 1 and .4 mg/L were considered as 1 and 8 mg/L and Vitek2 MICs of 0.5 and 16 mg/L were considered as 0.5 and 16 mg/L, respectively. Agreement and error rates were evaluated by applying the requirements suggested by ISO for susceptibility testing methods:
12 a method must exhibit CA and EA of 90% and VME/ME 3% to be considered acceptable.
Results and discussion
The susceptibilities to colistin produced by each method for the 117 study isolates and the EAs, CAs, MEs and VMEs are presented in Table 1 and the distribution of colistin MICs is presented in Table  2 . In brief, by Phoenix100, Vitek2 Compact, BMD and AD, 18 (15.4%), 19 (16.2%), 29 (24.8%) and 42 (35.9%) isolates were resistant, respectively. The EA rate was 91.5% for Phoenix100, 88.9% for Vitek2 and 93.2% for AD, while the CA rate was 88.9% for Phoenix100, 89.7% for Vitek2 and 87.2% for AD. By the automated systems, which overall underestimated colistin resistance levels, very limited ME rates of 1.1% for both Phoenix100 and Vitek2 were observed. Considerably more MEs were produced by AD (15.9%), which, as also shown previously, 13 produced higher MICs than BMD. Of particular concern, the automated systems yielded numerous VMEs: Phoenix100, 41.4%; and Vitek2, 37.9%. The rates of VMEs by both methods were considerably lower among isolates exhibiting MICs of 1 mg/L compared with those yielding an MIC of 2 mg/L, as determined by automated methods. In particular, by Phoenix100, 6/86 isolates with an MIC of 1 mg/L were resistant by BMD compared with 6/13 having an MIC of 2 mg/L; the respective figures for Vitek2 were 8/89 and 3/9. The rate of VMEs by AD was relatively limited (3.4%).
Colistin is currently used commonly as last-line treatment of infections caused by A. baumannii.
1 Despite the obvious necessity of determining accurately the in vitro activity of colistin, several methodological issues exist with the available AST assays. As commented by the EUCAST/CLSI working group, colistin AST by disc and gradient diffusion methods and also AD is not recommended and needs further validation until new study data have been generated, 2 with only BMD shown to be valid. Regarding the available Vitek2/Phoenix100 for colistin susceptibility testing JAC automated AST systems, Vitek2 and Phoenix were not appropriately evaluated and EUCAST/CLSI is not yet able to recommend their use for colistin AST. 2, 4 Furthermore, the US FDA has not cleared the commercial automated devices for colistin AST. We have previously tested Vitek2 in comparison with AD and BMD on a relatively small collection of 20 CRAB isolates with elevated colistin MICs. 3 In the present follow-up study we evaluated the performance of Vitek2 and Phoenix100 for colistin AST on a larger representative collection of CRAB clinical isolates from throughout Greece.
Few data are available relating to the performance of automated systems and they refer only to Vitek, which exhibited appropriate performance in colistin AST, being tested mostly on colistin-susceptible A. baumannii.
14-16 Also, in our previous study, 3 where 90% of the isolates were resistant to colistin, Vitek2 identified correctly all resistant isolates. 3 Nevertheless, one study that included several resistant isolates reported that Vitek2 colistin MICs were one to two 2-fold dilutions lower than those of BMD. 17 In the present study, which tested random contemporary CRAB clinical isolates, both automated systems produced comparable resistance rates, underestimating colistin MICs and misidentifying more than one-third of resistant isolates as susceptible. VMEs were much rarer by both systems for isolates with MICs of 1 rather than 2 mg/L, indicating that isolates with MIC values at the susceptibility breakpoint should be preferentially tested by a BMD assay. Finally, the other dilution method tested, AD, yielded considerably higher MICs and many MEs. Nevertheless, VMEs were very uncommon with AD and this would point to a potential role of AD in screening, particularly if colistin resistance is uncommon, while its applicability would be lower in regions, such as Greece, with relatively high colistin MICs among A. baumannii.
In conclusion, the VMEs observed by automated devices may have severe implications for treatment decisions, given that most A. baumannii are regularly resistant to most or all antibiotics. The importance of the issue is heightened by the known underperformance of the remaining commercial assays for colistin AST, such as gradient diffusion strips. These findings underline the need for intensive research to define the optimal method for colistin AST in routine laboratories.
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